Pemafibrate and Cardiovascular Risk in Type 2 Diabetes
A study has found that pemafibrate therapy in patients with type 2 diabetes does not decrease risk for cardiovascular events.
Source: endocrinologyadvisor.com
Reducing Triglycerides News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Reducing Triglycerides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Reducing Triglycerides Today - Breaking & Trending Today
New medication lowers triglyceride levels, yet does not decrease cardiovascular risk in people with Type 2 diabetes
A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes yet did not decrease their cardiovascular risk, according to late-breaking science research presented today at the American Heart Association's Scientific Sessions 2022.
Source: news-medical.net
ADA Updates on Finerenone, SGLT2 Inhibitors, and Race-Based eGFR
ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2 inhibitors, and eGFR.
Source: medscape.com